Wave Life Sciences Obesity Data Highlights Visceral Fat Focus Over Weight Loss

Wave Life Sciences (NasdaqGM:WVE) released new Phase 1 data for obesity candidate WVE-007 from its INLIGHT study. The therapy showed meaningful reductions in visceral fat and preservation of muscle ...
Investor's Business Daily on MSN

Wave Life Sciences crashes 50% as 'body composition' fat-loss drug underwhelms

Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss ...
Clinical Trials Arena on MSN

Wave’s stock crashes 50% on Phase I obesity data

Despite the Phase I data being less impressive than expected, Wave will still initiate the Phase IIa portion of the study.

Wave Life Sciences: WVE-007 Data Leaves Biotech Shaken And Stirred (Downgrade)

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

Wave Plunges More Than 50% After Obesity Shot Falls Short

Wave Life Sciences Ltd. shares plunged their most on record after a single, higher-dose shot of its weight-loss drug failed ...

Wave Life Sciences shares plummet on weight loss therapy update

Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007 ...
The Manila Times

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Viscer…

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted ...